CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

ravulizumab

Last Updated: November 19, 2020
Result type: Reports
Project Number: SR0623-000
Product Line: Reimbursement Review

Generic Name: ravulizumab

Brand Name: TBC

Manufacturer: Alexion Pharma Canada Corp

Therapeutic Area: Paroxysmal nocturnal hemoglobinuria.

Indications: ​For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: No

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedMay 27, 2019
Patient group input closedJuly 16, 2019
Clarification:

- Patient input submission received from Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC) and the Canadian Association of PNH Patients

Patient input summary sent for review to patient input groupsAugust 08, 2019
Patient group comments on input summary closedAugust 15, 2019
Clarification:

- Patient input summary feedback received

Submission receivedJuly 04, 2019
Submission acceptedJuly 18, 2019
Review initiatedJuly 23, 2019
Clarification:

- Submission temporarily suspended at the request of the sponsor

- Voluntarily withdrawn by the sponsor on November 19, 2020